When health care workers received the first doses of Pfizer-BioNTech’s Covid-19 vaccines on Monday after the vaccine got emergency approval from the FDA just days before, it was a triumph for science.
But the unprecedented success of vaccine makers’ sprint to market, just nine months after the first novel coronavirus was identified, may also be these vaccines’ greatest weakness: to some consumers, it seems too good to be true.
“Did they rush it due to the amount of attention the virus was getting, and also the amount of money the company that created one will end up getting?” asked Jamie Hickey, an entrepreneur based in Philadelphia.
